brenetafusp

Protein / enzyme therapeutic

Phase 3underway

Evidence outlook · registrational

Cutaneous Melanoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-10-16.

Company guidance: data expected later this year (Immunocore Holdings plc, 6 Nov 2026). “We expect to present clinical data for brenetafusp from the ovarian and lung cohorts in the Phase 1/2 trial at a medical conference later this year.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
Phase 2 (1)
Other / comorbidity
NCT07686367 · National Cancer Institute (NCI)
2027-01-19 – 2027-11-30 · Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial Sarcoma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04262466 · Immunocore Ltd
2020-02-25 – 2027-12 · Select Advanced Solid Tumors
What this study did

Competitive landscape

This drug's own stage for Cutaneous Melanoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Brenetafusp: this drugPhase 3Protein / enzyme therapeuticPRAME antigen presented on HLA-A*02:01not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signalNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow brenetafusp to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
Phase 3Advanced MelanomaRecruiting
Est. primary completion 2027-10-16 · NCT06112314 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma, Unresectable Myxoid Liposarcoma, Unresectable Synovial SarcomaNot yet recruiting
Est. primary completion 2027-11-30 · NCT07686367 · CT.gov ↗
What to watch

See the full readout calendar ↗